Most notably, in vivo experimental data are currently lacking to confirm whether ICT can similarly modulate the expression of CA9, UCK2, FABP5, and CYP2C9, as well as remodel the tumor immune microenvironment in living organisms. The gene discussed is CYP2C9; the disease is neoplasm.